Journal Scans
Immunomonitoring Results of a Phase II/III Study of Malignant Ascites Patients Treated With the Trifunctional Antibody Catumaxomab (Anti-EpCAM x Anti-CD3)
Immunologic Antitumor Mechanisms of Catumaxomab in Malignant Ascites
M Jager, A Schoberth, P Ruf, J Hess, M Hennig, B Schmalfeldt, P Wimberger, MA Strohlein, B Heissen, MM Heiss, H Lindhofer
20111001
2011 Nov 1
Cancer Res
Immunomonitoring Results of a Phase II/III Study of Malignant Ascites Patients Treated With the Trifunctional Antibody Catumaxomab (Anti-EpCAM x Anti-CD3)
Cancer Res. 2011 Nov 1;[Epub Ahead of Print], M Jager, A Schoberth, P Ruf, J Hess, M Hennig, B Schmalfeldt, P Wimberger, MA Strohlein, B Heissen, MM Heiss, H Lindhofer
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Malignant ascites is caused by accumulation of peritoneal fluid associated with dissemination of epithelial cancer cells from ovarian, endometrial, colon, gastric, and other solid tumors. Ascites occurs because of vessel obstruction, impaired lymphatic drainage, and increased fluid production. In addition, vascular endothelial growth factor (VEGF) secretion by peritoneal cells is increased. Catumaxomab is a trifunctional monoclonal antibody that selectively binds to tumor cells via epithelial cell...
